{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:02:05Z","timestamp":1794024125109,"version":"4.8.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.08.010","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T13:54:53Z","timestamp":1633010093000},"page":"6573-6584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["A Research and Development (R&amp;D) roadmap for influenza vaccines: Looking toward the future"],"prefix":"10.1016","volume":"39","author":[{"given":"Kristine A.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia T.","family":"Ostrowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Kraigsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Mehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Gellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine P.","family":"Golding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Moen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Osterholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Ampofo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cavaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-2302","authenticated-orcid":false,"given":"Cheryl","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-4078","authenticated-orcid":false,"given":"Rebecca","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Innis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3656-564X","authenticated-orcid":false,"given":"Gagandeep","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-4839","authenticated-orcid":false,"given":"Jacqueline","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-2183","authenticated-orcid":false,"given":"Punnee","family":"Pitisuttithum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Rudenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-9817","authenticated-orcid":false,"given":"Marilda","family":"Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.08.010_b0005","unstructured":"WHO. Global Influenza Strategy 2019-2030. WHO; 2019."},{"key":"10.1016\/j.vaccine.2021.08.010_b0010","unstructured":"CDC. Selecting Viruses for the Seasonal Flu Vaccine. Centers for Disease Control and Prevention; 2020. https:\/\/www.cdc.gov\/flu\/prevent\/vaccine-selection.htm [accessed May 2, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0015","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00797-19","article-title":"Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs","author":"Dhakal","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0020","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1093\/infdis\/jiy696","article-title":"Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens","volume":"219","author":"Zost","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0025","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/infdis\/jiz024","article-title":"Influenza immunization in low- and middle-income countries: preparing for next-generation influenza vaccines","volume":"219","author":"Ortiz","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0030","article-title":"Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic","volume":"2019","author":"Porter","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0035","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.08.010_b0040","unstructured":"World Health Organization. WHO preferred product characteristics for next generation influenza vaccines; 2017."},{"key":"10.1016\/j.vaccine.2021.08.010_b0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/hs.2020.0043","article-title":"Developing vaccines for SARS-CoV-2 and future epidemics and pandemics: applying lessons from past outbreaks","volume":"18","author":"Billington","year":"2020","journal-title":"Health Secur"},{"key":"10.1016\/j.vaccine.2021.08.010_b0050","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.coviro.2011.08.002","article-title":"Influenza virus vaccines: lessons from the 2009 H1N1 pandemic","volume":"1","author":"Broadbent","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0055","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/infdis\/jis535","article-title":"2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa\u2014successes and challenges","volume":"206","author":"Mihigo","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0060","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.vaccine.2011.11.092","article-title":"Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean","volume":"30","author":"Ropero-\u00c1lvarez","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0065","unstructured":"NIAID. The Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. About CIVICs. n.d. https:\/\/www.niaidcivics.org\/about-civics\/ [accessed February 18, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0070","unstructured":"European External Action Service (EEAS). EU \u2013 India joint call \u201cTowards a Next Generation Influenza Vaccine to Protect Citizens Worldwide.\u201d EEAS - European External Action Service - European Union External Action. n.d. https:\/\/eeas.europa.eu\/delegations\/india\/49007\/eu-%E2%80%93-india-joint-call-towards-next-generation-influenza-vaccine-protect-citizens-worldwide_en [accessed February 18, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0075","unstructured":"Bill and Melinda Gates Foundation. Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development; 2018. https:\/\/gcgh.grandchallenges.org\/challenge\/ending-pandemic-threat-grand-challenge-universal-influenza-vaccine-development [accessed May 3, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0085","first-page":"1","article-title":"Better, faster, stronger: mRNA vaccines show promise for influenza vaccination in older adults","author":"Bartley","year":"2021","journal-title":"Immunol Invest"},{"key":"10.1016\/j.vaccine.2021.08.010_b0090","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3389\/fimmu.2018.00600","article-title":"Novel platforms for the development of a universal influenza vaccine","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/vaccines9010026","article-title":"The next generation of influenza vaccines: towards a universal solution","volume":"9","author":"McMillan","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.08.010_b0100","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3390\/microorganisms8111745","article-title":"New technologies for influenza vaccines","volume":"8","author":"Rockman","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2021.08.010_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0110","first-page":"1","article-title":"Next-generation influenza vaccines: opportunities and challenges","author":"Wei","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.vaccine.2021.08.010_b0115","unstructured":"Moderna. Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines | Moderna, Inc.; 2021"},{"key":"10.1016\/j.vaccine.2021.08.010_b0120","unstructured":"Novavax. Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure; 2020."},{"key":"10.1016\/j.vaccine.2021.08.010_b0125","unstructured":"Sabin-Aspen Vaccine Science Policy Group. Accelerating the Development of a Universal Influenza Vaccine. Aspen Institute and Sabin Vaccine Institute; 2019."},{"key":"10.1016\/j.vaccine.2021.08.010_b0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vaccine.2018.11.037","article-title":"Global funders consortium for universal influenza vaccine development","volume":"37","author":"Bresee","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0135","unstructured":"IVR Roadmap Development Team. Influenza Vaccines R&D Roadmap. CIDRAP. n.d. https:\/\/www.cidrap.umn.edu\/IVR [accessed May 2, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0140","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2014.01.053","article-title":"Vaccines against sexually transmitted infections: the way forward","volume":"32","author":"Broutet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0145","unstructured":"International Energy Agency. Energy technology roadmaps: a guide to development and implementation; 2014. https:\/\/sustainabledevelopment.un.org\/content\/documents\/21079TechnologyRoadmapAguidetodevelopmentandimplementation.pdf [accessed February 18, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0150","unstructured":"WHO. Global Influenza Surveillance and Response System (GISRS). Global Influenza Surveillance and Response System (GISRS) n.d. https:\/\/www.who.int\/data\/gho\/data\/themes\/global-influenza-virological-surveillance [accessed February 18, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0155","unstructured":"GISAID. GISAID - Mission 2021. https:\/\/www.gisaid.org\/about-us\/mission\/ [accessed February 18, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0160","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.vaccine.2021.08.010_b0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1750-2659.2011.00277.x","article-title":"Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14\u201316 June 2010","volume":"6","author":"Ampofo","year":"2012","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2021.08.010_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008583","article-title":"Beyond clinical trials: evolutionary and epidemiological considerations for development of a universal influenza vaccine","volume":"16","author":"Viboud","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.08.010_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-39276-1","article-title":"Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011\u20132018","volume":"9","author":"Jorquera","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.08.010_b0180","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/21645515.2017.1423152","article-title":"Models for predicting the evolution of influenza to inform vaccine strain selection","volume":"14","author":"Agor","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.08.010_b0185","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/infdis\/jiz043","article-title":"Preparing for the next influenza pandemic: the development of a universal influenza vaccine","volume":"219","author":"Crank","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0190","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1080\/21645515.2018.1462639","article-title":"H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation","volume":"14","author":"Allen","year":"2018","journal-title":"Hum Vac Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.08.010_b0195","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/vaccines6020019","article-title":"Efforts to improve the seasonal influenza vaccine","volume":"6","author":"Harding","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.08.010_b0200","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2021.08.010_b0205","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/infdis\/jiy728","article-title":"Making universal influenza vaccines: lessons from the 1918 pandemic","volume":"219","author":"Morens","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0210","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/vaccines8030434","article-title":"Influenza A virus vaccination: immunity, protection, and recent advances toward a universal vaccine","volume":"8","author":"Lopez","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.08.010_b0215","first-page":"a038596","article-title":"Systems biological analysis of immune response to influenza vaccination","author":"Cortese","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2021.08.010_b0220","first-page":"a038729","article-title":"Immunity to influenza infection in humans","author":"Topham","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2021.08.010_b0225","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0230","doi-asserted-by":"crossref","first-page":"13474","DOI":"10.1073\/pnas.1816300116","article-title":"Outflanking immunodominance to target subdominant broadly neutralizing epitopes","volume":"116","author":"Angeletti","year":"2019","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2021.08.010_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2019.04.003","article-title":"Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope","author":"Bajic","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2021.08.010_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02997","article-title":"Recombinant influenza vaccines: saviors to overcome immunodominance","volume":"10","author":"Mathew","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01605","article-title":"Innovative mucosal vaccine formulations against influenza A virus infections","volume":"10","author":"Calzas","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0250","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kwy145","article-title":"Universal influenza vaccines: progress in achieving broad cross-protection in vivo","author":"Epstein","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0255","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1920321117","article-title":"Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies","author":"Arevalo","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2021.08.010_b0260","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s41467-019-09652-6","article-title":"Age-specific differences in the dynamics of protective immunity to influenza","volume":"10","author":"Ranjeva","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2021.08.010_b0265","doi-asserted-by":"crossref","first-page":"a038471","DOI":"10.1101\/cshperspect.a038471","article-title":"Influenza vaccines delivered in early childhood could turn antigenic sin into antigenic blessings","author":"Worobey","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2021.08.010_b0270","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/14760584.2017.1334554","article-title":"Repeated annual influenza vaccination and vaccine effectiveness: review of evidence","volume":"16","author":"Belongia","year":"2017","journal-title":"Expert Rev Vac"},{"key":"10.1016\/j.vaccine.2021.08.010_b0275","doi-asserted-by":"crossref","unstructured":"Kim SS, Flannery B, Foppa IM, Chung JR, Nowalk MP, Zimmerman RK, et al. Effects of prior season vaccination on current season vaccine effectiveness in the US Flu VE Network, 2012-13 through 2017-18. Clin Infect Dis 2020:ciaa706. https:\/\/doi.org\/10.1093\/cid\/ciaa706.","DOI":"10.1093\/cid\/ciaa706"},{"key":"10.1016\/j.vaccine.2021.08.010_b0280","first-page":"a040964","article-title":"Influenza immunization in the context of preexisting immunity","author":"Linderman","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2021.08.010_b0285","doi-asserted-by":"crossref","unstructured":"Richards KA, Shannon I, Treanor JJ, Yang H, Nayak JL, Sant AJ. Evidence that blunted CD4 T cells responses underlie deficient protective antibody responses to influenza vaccines in repeatedly vaccinated human subjects. J Infect Dis n.d. https:\/\/doi.org\/10.1093\/infdis\/jiz433.","DOI":"10.1093\/infdis\/jiz433"},{"key":"10.1016\/j.vaccine.2021.08.010_b0290","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","article-title":"Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination","volume":"119","author":"Jansen","year":"2019","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0295","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/erv.13.35","article-title":"Immunological assessment of influenza vaccines and immune correlates of protection","volume":"12","author":"Reber","year":"2013","journal-title":"Expert Rev Vac"},{"key":"10.1016\/j.vaccine.2021.08.010_b0300","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1016\/j.vaccine.2020.04.069","article-title":"Antibody responses to influenza A(H1N1)pdm infection","volume":"38","author":"Wraith","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0305","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/irv.12706","article-title":"Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines","volume":"14","author":"Krammer","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2021.08.010_b0310","first-page":"kwz227","article-title":"Distinguishing causation from correlation in the use of correlates of protection to evaluate and develop influenza vaccines","author":"Lim","year":"2019","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0315","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/vaccines8030361","article-title":"Prospects and challenges in the development of universal influenza vaccines","volume":"8","author":"Madsen","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.08.010_b0320","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.chom.2018.06.016","article-title":"Overcoming barriers in the path to a universal influenza virus vaccine","volume":"24","author":"Coughlan","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2021.08.010_b0325","first-page":"1","article-title":"The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity","author":"Gianchecchi","year":"2019","journal-title":"Hum Vac Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.08.010_b0330","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jpids\/piy057","article-title":"The influenza vaccine mess","volume":"7","author":"Plotkin","year":"2018","journal-title":"J Pediatr Infectious Dis Soc"},{"key":"10.1016\/j.vaccine.2021.08.010_b0335","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.coviro.2016.12.004","article-title":"Immune history and influenza virus susceptibility","volume":"22","author":"Cobey","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0340","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.coi.2018.05.010","article-title":"Harnessing immune history to combat influenza viruses","volume":"53","author":"Guthmiller","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0345","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From original antigenic sin to the universal influenza virus vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2021.08.010_b0350","unstructured":"CDC. CDC Seasonal Flu Vaccine Effectiveness Studies | CDC 2019. https:\/\/www.cdc.gov\/flu\/vaccines-work\/effectiveness-studies.htm [accessed May 3, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0355","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12889-019-6713-5","article-title":"Influenza epidemiology and influenza vaccine effectiveness during the 2016\u20132017 season in the Global Influenza Hospital Surveillance Network (GIHSN)","volume":"19","author":"Baselga-Moreno","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2021.08.010_b0360","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/cid\/ciz676","article-title":"Projected population benefit of increased effectiveness and coverage of influenza vaccination on influenza burden in the United States","volume":"70","author":"Hughes","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0365","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/infdis\/jiz017","article-title":"Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection","volume":"219","author":"Eichelberger","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0370","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3390\/vaccines8030409","article-title":"Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine","volume":"8","author":"Giurgea","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.08.010_b0375","doi-asserted-by":"crossref","first-page":"e02332","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines?","volume":"9","author":"Krammer","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2021.08.010_b0380","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/pharmaceutics13010068","article-title":"Promising adjuvants and platforms for influenza vaccine development","volume":"13","author":"Zhu","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.010_b0385","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","article-title":"Adjuvanted influenza vaccines","volume":"14","author":"Tregoning","year":"2018","journal-title":"Hum Vac Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.08.010_b0390","article-title":"Adjuvantation of influenza vaccines to induce cross-protective immunity","volume":"9","author":"Li","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2021.08.010_b0395","first-page":"a038448","article-title":"Next-generation influenza vaccines","author":"Kanekiyo","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2021.08.010_b0400","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/infdis\/jiy745","article-title":"New vaccine design and delivery technologies","volume":"219","author":"Kanekiyo","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0405","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","article-title":"Current and future influenza vaccines","volume":"25","author":"Yamayoshi","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.08.010_b0410","doi-asserted-by":"crossref","unstructured":"Amitai A, Sangesland M, Barnes RM, Rohrer D, Lonberg N, Lingwood D, et al. Defining and manipulating B cell immunodominance hierarchies to elicit broadly neutralizing antibody responses against influenza virus. Cell Syst 2020:S2405471220303355. https:\/\/doi.org\/10.1016\/j.cels.2020.09.005.","DOI":"10.2139\/ssrn.3586996"},{"key":"10.1016\/j.vaccine.2021.08.010_b0415","first-page":"1","article-title":"Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains","author":"De Jong","year":"2020","journal-title":"Expert Rev Vac"},{"key":"10.1016\/j.vaccine.2021.08.010_b0420","first-page":"1","article-title":"Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection","author":"Jang","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.vaccine.2021.08.010_b0425","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.08.010_b0430","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","article-title":"Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain","volume":"219","author":"Krammer","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0435","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/vaccines6030058","article-title":"The future of influenza vaccines: a historical and clinical perspective","volume":"6","author":"Bouvier","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.08.010_b0440","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1016\/j.vaccine.2018.10.024","article-title":"Workshop report: experimental animal models for universal influenza vaccines","volume":"36","author":"D\u2019Alessio","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0445","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/pathogens3040845","article-title":"Animal models for influenza viruses: implications for universal vaccine development","volume":"3","author":"Margine","year":"2014","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2021.08.010_b0450","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.vaccine.2020.01.101","article-title":"Workshop report: optimization of animal models to better predict influenza vaccine efficacy","volume":"38","author":"Lane","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0455","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1016\/j.vaccine.2019.06.080","article-title":"Meeting report: convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity","volume":"37","author":"Innis","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0460","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1016\/j.vaccine.2019.06.053","article-title":"Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: methodologic considerations","volume":"37","author":"Innis","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0465","unstructured":"Imperial College London. First volunteers on COVID-19 human challenge study leave quarantine | Imperial News | Imperial College London. Imperial News n.d. https:\/\/www.imperial.ac.uk\/news\/218294\/first-volunteers-covid-19-human-challenge-study\/ [accessed May 1, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0470","unstructured":"University of Oxford. Human challenge trial launches to study immune response to COVID-19 | University of Oxford n.d. https:\/\/www.ox.ac.uk\/news\/2021-04-19-human-challenge-trial-launches-study-immune-response-covid-19 [accessed May 1, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0475","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.vaccine.2020.12.018","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2019","volume":"39","author":"Sparrow","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0480","doi-asserted-by":"crossref","unstructured":"Rappuoli R, Black S, Bloom DE. Vaccines and global health: in search of a sustainable model in vaccine development and delivery. Sci Transl Med 2019;11(497):eaaw2888. doi: 10.1126\/scitranslmed.aaw2888.","DOI":"10.1126\/scitranslmed.aaw2888"},{"key":"10.1016\/j.vaccine.2021.08.010_b0485","unstructured":"Global Funders Consortium for Universal Influenza Vaccine Development. Meeting Report, November 2-3, 2017 n.d."},{"key":"10.1016\/j.vaccine.2021.08.010_b0490","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.25384","article-title":"Funding of pharmaceutical innovation during and after the COVID-19 pandemic","author":"Robinson","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.08.010_b0495","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1016\/j.vaccine.2017.09.048","article-title":"Estimating the full public health value of vaccination","volume":"35","author":"Gessner","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.010_b0500","doi-asserted-by":"crossref","DOI":"10.3201\/eid2502.180359","article-title":"Public health-driven research and innovation for next-generation influenza vaccines, European Union","volume":"25","author":"Navarro-Torn\u00e9","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.010_b0505","unstructured":"CARB-X. CARB-X. Carb-X n.d. https:\/\/carb-x.org\/ [accessed May 2, 2021]."},{"key":"10.1016\/j.vaccine.2021.08.010_b0510","unstructured":"CEPI. CEPI | New Vaccines For A Safer World. Coalition for Epidemic Preparedness Innovations n.d. https:\/\/cepi.net\/ (accessed February 18, 2021)."},{"key":"10.1016\/j.vaccine.2021.08.010_b0515","unstructured":"Secretariat for the Convention on Biological Diversity. The Nagoya Protocol on Access and Benefit-sharing 2021. https:\/\/www.cbd.int\/abs\/ (accessed May 2, 2021)."},{"key":"10.1016\/j.vaccine.2021.08.010_b0520","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/d41586-021-00340-4","article-title":"Variant-proof vaccines \u2013 invest now for the next pandemic","volume":"590","author":"Burton","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.08.010_b0525","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:03:08Z","timestamp":1759402988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21010288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":105,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X21010288"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}